Estrella Immunopharma, Inc.
ESLA
$0.94
-$0.0295-3.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | 12.69% | 12.69% | 34.21% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -100.00% | -100.00% | 191.67% |
| Change in Net Operating Assets | -- | -- | -213.68% | -213.68% | -206.22% |
| Cash from Operations | -- | -- | -3,423.89% | -3,423.89% | -1,102.63% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 1,416.61% | 1,416.61% | 1,917.07% |
| Cash from Investing | -- | -- | 1,416.61% | 1,416.61% | 1,917.07% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -309.97% | -309.97% | -- |
| Cash from Financing | -- | -- | -136.93% | -136.93% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -206.22% | -206.22% | 204.78% |